The lead-in, the randomisation, and the year that followed
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
The Ledger
Page 21 of 25 of this archive, newest first.
Page 21
Germany caps tirzepatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What the placebo arms of the withdrawal trials actually tell us
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Mexico declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Denmark declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Turkey caps semaglutide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The badge economy, and what it is actually certifying
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
Turkey caps liraglutide prescribing to 8 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
New Zealand declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
New Zealand caps semaglutide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Poland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
The shortage years, and what they taught about interruption
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Argentina declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
A tested vial is evidence about a vial
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
We split six vials four ways and posted them
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
Germany caps dulaglutide prescribing to 24 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Mexico declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The withdrawal trials, read as designs rather than warnings
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.